Craig A. Erickson, MD

Academic Affiliation

Associate Professor

UC Department of Psychiatry and Behavioral Neuroscience

Phone 513-636-8375

Email craig.erickson@cchmc.org

Fragile X syndrome; autism spectrum disorders

Visit the Erickson-Wink Lab.

Dr. Erickson has worked to obtain continuous federal, foundation, internal, and industry funding supporting his and his collaborators' research over the last 10 ten years of his career. He is the inventor or co-inventor on many patents focused on translational treatment development in neurodevelopmental disorders that are held at Cincinnati Children's Hospital Medical Center and at his previous employer the Indiana University School of Medicine. He is considered an international expert in the clinical treatment of fragile X syndrome and has similar expertise in fragile X-specific clinical trial development. Dr. Erickson is additionally an avid teacher of future generations of child psychiatrists has received several teaching awards for his work in physician education. He also enjoys mentoring junior faculty in the behavioral and developmental neuropsychiatry sub-field of child psychiatry.

Specifically in research, he and his colleagues have moved forward several repurposed molecules for study in fragile X syndrome and autism spectrum disorder including work with acamprosate, riluzole, ketamine, D cycloserine, and N acetyl cysteine among other repurposed molecules. He also is working now to move several novel molecules into autism and fragile X-specific study using proprietary compounds abandoned from initially intended use that may hold promise in the disorders which he and his colleagues study.

MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2003.

MS: Indiana University School of Medicine, Indianapolis, IN, 2008.

Residency and Fellowship: Indiana University School of Medicine, Indianapolis, IN, 2003-2008.

Certification: Child and Adolescent Psychiatry, 2009; Adult Psychiatry, 2008.

View PubMed Publications

Erickson CA, Ray B, Wink LK, Bayon BL, Pedapati EV, Shaffer R, Schaefer TL, Lahiri DK. Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism. J Psychiatr Res. 2016 Sep 9;84:153-160.

Fitzpatrick SE, Srivorakiat L, Wink LK, Pedapati EV, Erickson CA. Aggression in autism spectrum disorder: presentation and treatment options. Neuropsychiatr Dis Treat. 2016 Jun 23;12:1525-38.

Erickson CA, Wink LK, Baindu B, Ray B, Schaefer TL, Pedapati EV, Lahiri DK. Analysis of peripheral amyloid precursor protein in Angelman Syndrome. Am J Med Genet A. 2016 Sep;170(9):2334-7.

Wink LK, Adams R, Wang Z, Klaunig JE, Plawecki MH, Posey DJ, McDougle CJ, Erickson CA. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism. 2016 Apr 21;7:26.

Minshawi NF, Wink LK, Shaffer R, Plawecki MH, Posey DJ, Liu H, Hurwitz S, McDougle CJ, Swiezy NB, Erickson CA. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Mol Autism. 2016 Jan 14;7:2.

Wink LK, Pedapati EV, Horn PS, McDougle CJ, Erickson CA. Multiple Antipsychotic Medication Use in Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2015 Oct 14.

Wink LK, Fitzpatrick S, Shaffer R, Melnyk S, Begtrup AH, Fox E, Schaefer TL, Mathieu-Frasier L, Ray B, Lahiri D, Horn PA, Erickson CA. The neurobehavioral and molecular phenotype of Angelman Syndrome. Am J Med Genet A. 2015 Nov;167A(11):2623-8.

Dominick K, Wink LK, McDougle CJ, Erickson CA. A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2015 Jun;25(5):397-401.

Schaefer TL, Davenport MH, Erickson CA. Emerging pharmacologic treatment options for fragile X syndrome. Appl Clin Genet. 2015 Apr 7;8:75-93.

Erickson CA, Ray B, Maloney B, Wink LK, Bowers K, Schaefer TL, McDougle CJ, Sokol DK, Lahiri DK. Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J Psychiatr Res. 2014 Dec;59:220-8.

John Merck Fund Translational Research Program Award. Principal Investigator. The John Merck Fund. Jan 2013-Dec 2016.

Autism Inpatient Collection Grant. Site Co-Investigator. Simons Foundation and Nancy Lurie Marks Foundation. Oct 2015-Sep 2018.

Fragile X Clinical and Research Consortium Forward Registry and Database. Principal Investigators. Cincinnati Children’s Hospital Medical Center Site. Sept 2012-Dec 2020.